Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Opthea Limited
  6. Summary
    OPT   AU000000OPT2

OPTHEA LIMITED

(OPT)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
1.265 1.275 1.335 1.32 1.295 Last
521924 2787303 1108281 315603 574555 Volume
+2.02% +0.79% +4.71% -1.12% -1.89% Change
Estimated financial data (e)
Sales 2021 0,50 M 0,37 M 0,37 M
Net income 2021 -65,6 M -48,3 M -48,3 M
Net cash position 2021 192 M 141 M 141 M
P/E ratio 2021 -5,83x
Yield 2021 0,02%
Sales 2022 0,38 M 0,28 M 0,28 M
Net income 2022 -93,3 M -68,6 M -68,6 M
Net cash position 2022 85,0 M 62,6 M 62,6 M
P/E ratio 2022 -4,24x
Yield 2022 -
Capitalization 455 M 335 M 335 M
EV / Sales 2021 524x
EV / Sales 2022 964x
Nbr of Employees -
Free-Float 84,5%
More Financials
Company
Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies primarily for eye diseases. The Company operates in medical technology and healthcare industry in Australia. The Company is involved in the development activities, which are based on the intellectual property portfolio covering key targets, such as vascular endothelial growth factors [VEGF]-C, -D and VEGF... 
More about the company
Ratings of Opthea Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about OPTHEA LIMITED
07/06OPTHEA : Wins FDA Fast Track Designation for Wet Age-Related Macular Degeneratio..
MT
07/06Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macul..
GL
07/06OPTHEA : OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular ..
PU
07/06Opthea OPT-302 Granted Fast Track Designation from FDA
DJ
07/05Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macul..
CI
06/22OPTHEA : Total number of +securities proposed to be issued for a placement or ot..
PU
06/15OPTHEA : Names New Company Secretary, Vice President of Finance
MT
06/14OPTHEA : Appoints Company Secretary and Vice President of Finance (Form 6-K)
PU
06/14OPTHEA : Appoints Company Secretary and Vice President of Finance
AQ
06/14Opthea Limited Appoints Karen Adams as Company Secretary and Vice President o..
CI
06/01Opthea Appoints Julia A. Haller, MD, and Judith Robertson toáBoard of Directo..
GL
06/01Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directo..
CI
04/12GENETIC TECHNOLOGIES : Names Mike Tonroe as Finance Chief
MT
04/12GENETIC TECHNOLOGIES : Names CFO
MT
04/06OPTHEA : Finance Chief to Step Down
MT
More news
News in other languages on OPTHEA LIMITED

- No features available -

More news
Analyst Recommendations on OPTHEA LIMITED
More recommendations
Chart OPTHEA LIMITED
Duration : Period :
Opthea Limited Technical Analysis Chart | OPT | AU000000OPT2 | MarketScreener
Technical analysis trends OPTHEA LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,30 AUD
Average target price 3,93 AUD
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Megan Baldwin Chief Executive Officer, Executive Director & MD
Karen Adams Secretary & Vice President-Finance
Jeremy Max Levin Chairman
Michael K. Sistenich Independent Non-Executive Director
Lawrence B. Gozlan Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
OPTHEA LIMITED-32.55%335
MODERNA, INC.214.44%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.35.73%47 396
CELLTRION, INC.-26.60%31 265
SEAGEN INC.-17.54%25 955